drugset / Trial / NCT06978907

Evaluation of the Efficacy and Safety of Lactobacillus Crispatus M247 (Crispact®) With Vaginal Laser Therapy in Menopausal Women With Atrophic Vulvovaginitis (VVA)

NCT06978907 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized, controlled, prospective, multicenter study aims to evaluate the efficacy and safety of Lactobacillus crispatus M247 in combination with vaginal laser therapy for improving vaginal microbiota composition and reducing genitourinary symptoms in menopausal women with atrophic vulvovaginitis (VVA). Participants will be randomized into two groups: one receiving laser therapy alone and the other receiving laser therapy combined with daily administration of the probiotic Lactobacillus crispatus M247 (Crispact®). Primary outcomes include changes in genitourinary symptoms assessed using a validated vulvovaginal symptom questionnaire and evaluation of safety. Secondary outcomes include changes in vaginal microbiota composition.

Timeline

Start
2025-07-01
Primary completion
2025-11-27
Completion
2025-12-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus Crispatus M247 Unknown 2e+10 cells Oral

Indications